DGAP-News: Biotest AG
/ Key word(s): Statement
Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept takeover offer of GRIFOLS, S.A.
Dreieich, 5 November 2021. Today, the Management Board and the Supervisory Board of Biotest AG ("Biotest") have published their joint reasoned statement pursuant to Section 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz) on the offer document of GRIFOLS, S.A. ("Bidder") dated 26 October 2021. The Biotest works council has given its own statement, which has been published as an annex to the statement of the Management Board and the Supervisory Board.
In this statement, the Management Board and the Supervisory Board recommend, after a careful review process, to the shareholders to accept the offer. This recommendation is explained in more detail in the joint reasoned statement.
After a thorough review, the Management Board and the Supervisory Board have independently come to the conclusion that the consideration offered by the Bidder is fair within the meaning of Section 31 para. 1 WpÜG and that the implementation of the offer is in the interest of Biotest and its shareholders. In assessing the adequacy of the offer from a financial point of view, the Management Board and the Supervisory Board of Biotest were advised by Rothschild & Co. Rothschild & Co concludes in its Fairness Opinion that the offer is fair to Biotest shareholders from a financial point of view.
The Management Board and the Supervisory Board of Biotest see in the business combination a concrete opportunity to combine the existing resources of the Bidder and Biotest in the field of blood plasma in order to achieve a greater availability of resources as well as a larger product range. The Bidder's intended increase of available resources for Biotest's research and development departments could also drive product development and manufacturing faster than would be possible for Biotest as an individual company.
The complete joint reasoned statement of the Management Board and the Supervisory Board of Biotest can be accessed on the company's website at the following link under the heading Investor Relations (in the section "Takeover offer"):
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
05.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Phone:||0 61 03 - 8 01-0|
|Fax:||0 61 03 - 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1246482|
|End of News||DGAP News Service|